Plasma Derived Therapy Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Plasma Derived Therapy Market Size Analysis and Top Companies

The plasma derived therapy market size is expected to worth around USD 39.90 billion by 2033 from USD 20.47 billion in 2023 with a CAGR of 6.9%. The major players operating in the plasma derived therapy market are CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, SA, Kedrion and Pfizer.

Market Report Coverage

Plasma Derived Therapy Key Players

• CSL Behring
• Takeda Pharmaceutical Company Limited
• BPL
• ADMA Biologics
• Biotest AG
• Octapharma
• Grifols
• Kamada Pharmaceuticals
• SK Plasma
• SA
• Kedrion
• Pfizer

Recent Developments

• In July 2020 - a leading producer of plasma derived medicines, Grifols signed an agreement with the company of GC pharma with a view to take over the plasma fractionation facility based in Montreal along with the other plasma collection centers that are based in the US and two facilities of purification. The company was able to expand its limits and boost the market revenue with the help of this strategic movement. The leading position of the company was maintained with this deal. 

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344